Research progress of single cell sequencing technique in predicting the immunotherapeutic efficacy of lung cancer
10.3760/cma.j.cn121382-20210802-00115
- VernacularTitle:单细胞测序技术在预测肺癌免疫疗效中的研究进展
- Author:
Wei WEI
1
;
Jianquan ZHU
;
Yanjun SU
Author Information
1. 天津医科大学肿瘤医院肺部肿瘤科，国家恶性肿瘤临床医学研究中心，天津市恶性肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津 300060
- Keywords:
Lung cancer;
Single-cell sequencing;
Tumor microenvironment;
Immunotherapy
- From:
International Journal of Biomedical Engineering
2022;45(1):68-72
- CountryChina
- Language:Chinese
-
Abstract:
Globally, lung cancer is the leading cause of cancer death. Although survival rates for lung cancer patients have improved over the past few decades, the survival rates have not yet reached the levels of other common malignancies. In recent years, immune checkpoint inhibitors (ICIs) have shown great promise in clinical trials and have been rapidly incorporated into the standard of care for patients with advanced non-small cell lung cancer (NSCLC). However, many patients do not benefit from treatment. Our findings suggest that the heterogeneity of the tumor microenvironment (TME) is closely related to the efficacy of ICIs. Single-cell sequencing is a technology that can specifically analyze cell populations at the genome and transcriptome levels at the single-cell level. This article reviews the potential value of single-cell sequencing technology in predicting immune responses to lung cancer.
